X

FDA Approves Pricey New Breast Cancer Drug

Full course of Roche's Kadcyla will cost $94K
By Newser Editors and Wire Services
Posted Feb 22, 2013 12:20 PM CST
FDA Approves Pricey New Breast Cancer Drug
A file photo of Swiss pharmaceutics company Roche in Basel, Switzerland.   (AP Photo/Keystone, Steffen Schmidt)

(Newser) – The FDA has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones. The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a double-shot of anti-tumor poison. Cancer researchers say the drug, which will cost nearly $10,000 a month, may offer a clear advantage over older drugs because it delivers more medication with fewer side effects.

story continues below

The FDA approved the new treatment for about 20% of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year. Genentech said Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000. (Read more Kadcyla stories.)

We use cookies. By Clicking "OK" or any content on this site, you agree to allow cookies to be placed. Read more in our privacy policy.
Get the news faster.
Tap to install our app.
X
Install the Newser News app
in two easy steps:
1. Tap in your navigation bar.
2. Tap to Add to Home Screen.

X